HS-276 is an orally active, potent, and highly selective TAK1 inhibitor with a Ki of 2.5 nM. It significantly inhibits multiple kinases including TAK1, CLK2, GCK, ULK2, MAP4K5, IRAK1, NUAK, CSNK1G2, CAMKKβ-1, and MLK1. It reduces the expression of TNF, IL-6, and IL-1β in a dose-dependent manner and shows excellent bioavailability in mice, making it suitable for rheumatoid arthritis (RA) research.
- Orally active and highly selective TAK1 inhibitor
- Significant inhibition of multiple kinases
- Reduces expression of inflammatory cytokines
- Demonstrates excellent bioavailability in vivo
- Suitable for rheumatoid arthritis research